It has been suggested that inhibition of IDO could be an important strategy to activate antitumor immunity by targeting tumor metabolism, however, clinical testing of experimental IDO inhibitors have shown disappointing results [86, 87]. This evidence concerns the gene IDO1 and neoplasm.